HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 286/4/L694    most recent 00204.2003v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (14) Citing Articles via Google Scholar Google Scholar Articles by Yu, J. Articles by Henske, E. P. Search for Related Content PubMed PubMed Citation Articles by Yu, J. Articles by Henske, E. P.

TRANSLATIONAL PHYSIOLOGY

EDITORIAL FOCUS

Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways

Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111

Submitted 25 June 2003 ; accepted in final form 13 August 2003

Lymphangioleiomyomatosis (LAM) is a progressive lung disease affecting almost exclusively women. The reasons for this strong gender predisposition are poorly understood. Renal angiomyolipomas occur in 50–60% of sporadic LAM patients. The smooth muscle cells of pulmonary LAM and renal angiomyolipomas are nearly indistinguishable morphologically. Here, we report the first successful cell culture of a LAM-associated renal angiomyolipoma. The cells carried inactivating mutations in both alleles of the TSC2 gene and expressed estrogen receptor , estrogen receptor , and androgen receptor. To elucidate the cellular pathways through which steroid hormones influence LAM pathogenesis, we treated the cells with both estradiol and tamoxifen. Cell growth was stimulated by estradiol, associated with phosphorylation of p44/42 MAPK at 5 min and an increase in c-myc expression at 4 h. Tamoxifen citrate also stimulated cell growth, associated with increased phosphorylation of p44/42 MAPK and expression of c-myc, indicating that tamoxifen has agonist effects on angiomyolipoma cells. This response to tamoxifen in human angiomyolipoma cells differs from prior studies of Eker rat leiomyoma cells, possibly reflecting cell type or species differences in cells lacking tuberin. Our data provide the first evidence that estradiol stimulates the growth of angiomyolipoma cells, that tamoxifen has agonist effects in angiomyolipoma cells, and that estradiol and tamoxifen impact both genomic and nongenomic signaling pathways in angiomyolipoma cells. The responsiveness of angiomyolipoma cells to estradiol may be related to the underlying reasons that LAM affects primarily women.

tuberous sclerosis complex; mitogen-activated protein kinase; tuberin; hamartin; estrogen receptor; lymphangioleiomyomatosis

This article has been cited by other articles:

				D. Clements, S. L Asprey, T. A McCulloch, T. A Morris, S. A Watson, and S. R Johnson Analysis of the oestrogen response in an angiomyolipoma derived xenograft model Endocr. Relat. Cancer, March 1, 2009; 16(1): 59 - 72. [Abstract] [Full Text] [PDF]

				J. J. Yu, V. A. Robb, T. A. Morrison, E. A. Ariazi, M. Karbowniczek, A. Astrinidis, C. Wang, L. Hernandez-Cuebas, L. F. Seeholzer, E. Nicolas, et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells PNAS, February 24, 2009; 106(8): 2635 - 2640. [Abstract] [Full Text] [PDF]

				S. P. Yun, M. Y. Lee, J. M. Ryu, C. H. Song, and H. J. Han Role of HIF-1{alpha} and VEGF in human mesenchymal stem cell proliferation by 17{beta}-estradiol: involvement of PKC, PI3K/Akt, and MAPKs Am J Physiol Cell Physiol, February 1, 2009; 296(2): C317 - C326. [Abstract] [Full Text] [PDF]

				F. X. McCormack Lymphangioleiomyomatosis: A Clinical Update Chest, February 1, 2008; 133(2): 507 - 516. [Abstract] [Full Text] [PDF]

				A. G. Schwartz, A. S. Wenzlaff, G. M. Prysak, V. Murphy, M. L. Cote, S. C. Brooks, D. F. Skafar, and F. Lonardo Reproductive Factors, Hormone Use, Estrogen Receptor Expression and Risk of Non Small-Cell Lung Cancer in Women J. Clin. Oncol., December 20, 2007; 25(36): 5785 - 5792. [Abstract] [Full Text] [PDF]

				S. C. Juvet, F. X. McCormack, D. J. Kwiatkowski, and G. P. Downey Molecular Pathogenesis of Lymphangioleiomyomatosis: Lessons Learned from Orphans Am. J. Respir. Cell Mol. Biol., April 1, 2007; 36(4): 398 - 408. [Abstract] [Full Text] [PDF]

				S. Zarogiannis, C. Hatzoglou, P. A. Molyvdas, and K. Gourgoulianis Lymphangioleiomyomatosis Eur. Respir. J., December 1, 2006; 28(6): 1284 - 1284. [Full Text] [PDF]

				A. G. Schwartz, G. M. Prysak, V. Murphy, F. Lonardo, H. Pass, J. Schwartz, and S. Brooks Nuclear Estrogen Receptor {beta} in Lung Cancer: Expression and Survival Differences by Sex Clin. Cancer Res., October 15, 2005; 11(20): 7280 - 7287. [Abstract] [Full Text] [PDF]

				J. L. Black, Q. Ge, S. Boustany, P. R. A. Johnson, M. H. Poniris, A. R. Glanville, B. G. G. Oliver, L. M. Moir, and J. K. Burgess In vitro studies of lymphangioleiomyomatosis Eur. Respir. J., October 1, 2005; 26(4): 569 - 576. [Abstract] [Full Text] [PDF]

				G. Finlay The LAM cell: what is it, where does it come from, and why does it grow? Am J Physiol Lung Cell Mol Physiol, April 1, 2004; 286(4): L690 - L693. [Full Text] [PDF]